Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 97

1.

In vitro HIV-1 evolution in response to triple reverse transcriptase inhibitors & in silico phenotypic analysis.

Rath BA, Yousef KP, Katzenstein DK, Shafer RW, Schütte C, von Kleist M, Merigan TC.

PLoS One. 2013 Apr 17;8(4):e61102. doi: 10.1371/journal.pone.0061102.

2.

Persistence versus reversion of 3TC resistance in HIV-1 determine the rate of emergence of NVP resistance.

Rath BA, Olshen RA, Halpern J, Merigan TC.

Viruses. 2012 Aug;4(8):1212-34. doi: 10.3390/v4081212.

3.

Hypersusceptibility to non-nucleoside reverse transcriptase inhibitors in HIV-1: clinical, phenotypic and genotypic correlates.

Whitcomb JM, Huang W, Limoli K, Paxinos E, Wrin T, Skowron G, Deeks SG, Bates M, Hellmann NS, Petropoulos CJ.

AIDS. 2002 Oct 18;16(15):F41-7.

PMID:
12370521
4.

Combinations of mutations in the connection domain of human immunodeficiency virus type 1 reverse transcriptase: assessing the impact on nucleoside and nonnucleoside reverse transcriptase inhibitor resistance.

Gupta S, Fransen S, Paxinos EE, Stawiski E, Huang W, Petropoulos CJ.

Antimicrob Agents Chemother. 2010 May;54(5):1973-80. doi: 10.1128/AAC.00870-09.

6.

Mutations in the non-nucleoside binding-pocket interfere with the multi-nucleoside resistance phenotype.

Van Laethem K, Witvrouw M, Pannecouque C, Van Remoortel B, Schmit JC, Esnouf R, Kleim JP, Balzarini J, Desmyter J, De Clercq E, Vandamme AM.

AIDS. 2001 Mar 30;15(5):553-61.

PMID:
11316991
7.

Measuring enzymatic HIV-1 susceptibility to two reverse transcriptase inhibitors as a rapid and simple approach to HIV-1 drug-resistance testing.

Hoffmann D, Garcia AD, Harrigan PR, Johnston IC, Nakasone T, García-Lerma JG, Heneine W.

PLoS One. 2011;6(7):e22019. doi: 10.1371/journal.pone.0022019.

8.

Characterization of drug-resistance mutations in HIV type 1 isolates from drug-naive and ARV-treated patients in Bulgaria.

Santoro MM, Ciccozzi M, Alteri C, Montieri S, Alexiev I, Dimova I, Ceccherini-Silberstein F, Beshkov D, Rezza G, Perno CF.

AIDS Res Hum Retroviruses. 2008 Sep;24(9):1133-8. doi: 10.1089/aid.2008.0042.

9.

Drug-resistant reverse transcriptase genotyping and phenotyping of B and non-B subtypes (F and A) of human immunodeficiency virus type I found in Brazilian patients failing HAART.

Caride E, Brindeiro R, Hertogs K, Larder B, Dehertogh P, Machado E, de Sá CA, Eyer-Silva WA, Sion FS, Passioni LF, Menezes JA, Calazans AR, Tanuri A.

Virology. 2000 Sep 15;275(1):107-15.

10.

Resistance pathways of human immunodeficiency virus type 1 against the combination of zidovudine and lamivudine.

Theys K, Deforche K, Libin P, Camacho RJ, Van Laethem K, Vandamme AM.

J Gen Virol. 2010 Aug;91(Pt 8):1898-908. doi: 10.1099/vir.0.022657-0.

PMID:
20410311
11.

Tenofovir-based regimens associated with less drug resistance in HIV-1-infected Nigerians failing first-line antiretroviral therapy.

Etiebet MA, Shepherd J, Nowak RG, Charurat M, Chang H, Ajayi S, Elegba O, Ndembi N, Abimiku A, Carr JK, Eyzaguirre LM, Blattner WA.

AIDS. 2013 Feb 20;27(4):553-61. doi: 10.1097/QAD.0b013e32835b0f59.

PMID:
23079810
12.
13.

Amino acid mutation N348I in the connection subdomain of human immunodeficiency virus type 1 reverse transcriptase confers multiclass resistance to nucleoside and nonnucleoside reverse transcriptase inhibitors.

Hachiya A, Kodama EN, Sarafianos SG, Schuckmann MM, Sakagami Y, Matsuoka M, Takiguchi M, Gatanaga H, Oka S.

J Virol. 2008 Apr;82(7):3261-70. doi: 10.1128/JVI.01154-07.

14.

Modest decreases in NNRTI susceptibility do not influence virological outcome in patients receiving initial NNRTI-containing triple therapy.

Harrigan PR, Hertogs K, Verbiest W, Larder B, Yip B, Brumme ZL, Alexander C, Tilley J, O'Shaughnessy MV, Montaner JS.

Antivir Ther. 2003 Oct;8(5):395-402.

PMID:
14640386
15.

The challenge of antiretroviral-drug-resistant HIV: is there any possible clinical advantage?

Zaccarelli M, Tozzi V, Perno CF, Antinori A.

Curr HIV Res. 2004 Jul;2(3):283-92. Review.

PMID:
15279592
16.
18.

Insertions in the reverse transcriptase increase both drug resistance and viral fitness in a human immunodeficiency virus type 1 isolate harboring the multi-nucleoside reverse transcriptase inhibitor resistance 69 insertion complex mutation.

Quiñones-Mateu ME, Tadele M, Parera M, Mas A, Weber J, Rangel HR, Chakraborty B, Clotet B, Domingo E, Menéndez-Arias L, Martínez MA.

J Virol. 2002 Oct;76(20):10546-52.

19.

Effect of concurrent zidovudine use on the resistance pathway selected by abacavir-containing regimens.

Lanier ER, Givens N, Stone C, Griffin P, Gibb D, Walker S, Tisdale M, Irlbeck D, Underwood M, St Clair M, Ait-Khaled M.

HIV Med. 2004 Nov;5(6):394-9.

20.

Anti-human immunodeficiency virus type 1 activity of the nonnucleoside reverse transcriptase inhibitor GW678248 in combination with other antiretrovirals against clinical isolate viruses and in vitro selection for resistance.

Hazen RJ, Harvey RJ, St Clair MH, Ferris RG, Freeman GA, Tidwell JH, Schaller LT, Cowan JR, Short SA, Romines KR, Chan JH, Boone LR.

Antimicrob Agents Chemother. 2005 Nov;49(11):4465-73.

Supplemental Content

Support Center